- Kremoint Pharma Pvt. Ltd
- Vega Pharma Ltd.
- Jiangxi Bolai Pharmacy Co., Ltd.
- Xian Wison Biological Technology Co., Ltd.
- Hangzhou Uniwise International Co., Ltd.
- HuvePharma
- Yi Chang Veterinary Medicine Factory
- Medson Pharmaceuticals
- Medico Remedies Pvt. Ltd.
- Cipla Limited
- Pfizer Inc.
- Allergan plc
- Novartis AG
- Johnson and Johnson
- Bristol Myers Squibb Company
(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent developments by key players in the Aminoglycosides Market:
The COVID-19 outbreak profoundly impacted the healthcare sector, leading to various research endeavors to find potential treatments. Among the drugs scrutinized, aminoglycosides garnered attention for their potential as antiviral agents against SARS-CoV-2, the virus responsible for COVID-19. Studies published in 2021 revealed that aminoglycosides like hygromycin B (hygB) and neomycin demonstrated inhibition of the murine hepatitis virus (MHV) in laboratory settings, indicating their possible utility in developing potent COVID-19 medicinal compounds. An escalating occurrence of animal disease outbreaks also played a role in driving the demand for aminoglycosides. Veterinary medicine increasingly utilized antibiotics, including aminoglycosides, to combat bacterial infections in animals, contributing to the overall market growth. The aminoglycosides market is also being driven by the growing number of bacterial infectious diseases among the elderly population. As people age, their susceptibility to bacterial infections increases, leading to a higher demand for antibiotics like aminoglycosides, known for their bactericidal activity against specific bacteria. Antibiotic resistance and multidrug-resistant organisms (MRO) present a pressing healthcare challenge. To tackle this issue, the consumption of broad-spectrum antibiotics, including aminoglycosides, has risen considerably. These drugs are often employed as a secondary line of defence against infections resistant to standard antibacterial agents.
The burden of tuberculosis (TB) has also been a driving force in the demand for aminoglycosides, particularly in low-income countries where TB incidence remains alarmingly high. The effectiveness of aminoglycosides, especially against mycobacteria, makes them a critical component in combating this infectious disease. However, the market growth of aminoglycosides may encounter limitations due to their associated side effects. Drugs in this class, though effective, can lead to severe ototoxicity, nephrotoxicity, and neuromuscular blockade. As a result, the prescription rate of aminoglycosides might decrease as healthcare professionals balance their benefits with potential risks, especially in long-term treatments.